Related references
Note: Only part of the references are listed.Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Maurizio Callari et al.
CLINICAL CANCER RESEARCH (2016)
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Christos Hatzis et al.
CLINICAL CANCER RESEARCH (2016)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Moritz Gerstung et al.
NATURE COMMUNICATIONS (2015)
Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas
Edmund A. Mroz et al.
PLOS MEDICINE (2015)
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
Esther H. Lips et al.
BREAST CANCER RESEARCH (2015)
3 Multigene prognostic tests in breast cancer: past, present, future
Balazs Gyorffy et al.
BREAST CANCER RESEARCH (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
Tingting Jiang et al.
BMC GENOMICS (2014)
Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
Svasti Haricharan et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance
Charlotte K. Y. Ng et al.
CANCER RESEARCH (2014)
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit et al.
CLINICAL CANCER RESEARCH (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Prognostic Ease and Difficulty of Invasive Breast Carcinoma
Ali Tofigh et al.
CELL REPORTS (2014)
SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
Christopher A. Miller et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Y. Xu et al.
ANNALS OF ONCOLOGY (2013)
Cancer heterogeneity: implications for targeted therapeutics
R. Fisher et al.
BRITISH JOURNAL OF CANCER (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes
Lawrence A. Donehower et al.
JOURNAL OF PATHOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Nicolai Juul Birkbak et al.
PLOS ONE (2013)
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Otto Metzger-Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival
David L. Masica et al.
CANCER RESEARCH (2011)
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Jessica L. L. Robinson et al.
EMBO JOURNAL (2011)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Banu Arun et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R. West et al.
BREAST CANCER RESEARCH (2011)
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody et al.
BREAST CANCER RESEARCH (2011)
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
Giampaolo Bianchini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor Transcriptome Sequencing Reveals Allelic Expression Imbalances Associated with Copy Number Alterations
Brian B. Tuch et al.
PLOS ONE (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer
Valgerdur Birgisdottir et al.
BREAST CANCER RESEARCH (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Share Paper
